UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results November 7, 2018 at 4:05 PM EST PDF Version SAN FRANCISCO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported third quarter 2018 financial results. "We finished the third quarter well-positioned to drive our clinical and pre-clinical senescence programs forward, while continuing to explore other mechanisms implicated in diseases of aging," said Keith Leonard, chairman and chief executive officer of UNITY. “Our Phase 1 clinical trial evaluating the safety and tolerability of UBX0101 in moderate to severe osteoarthritis of the knee is ongoing and on track to read out in the first quarter of next year.” UNITY remains on schedule to file two additional Investigational New Drug (IND) applications in the second half of 2019. The most advanced pre-clinical candidates being evaluated for IND filings are targeted at ophthalmologic diseases. Third Quarter Financial Results Cash, cash equivalents and investments totaled $184.2 million as of September 30, 2018 compared with $92.2 million as of December 31, 2017. Operating loss for the three months ended September 30, 2018 was $19.4 million compared with $12.1 million for the same period in 2017. The increase includes non-cash stock-based compensation expense of $2.2 million, non-cash contingent consideration of $0.6 million and depreciation expense of $0.1 million. Cash used for operations during the third quarter of 2018 was $13.9 million, which includes cash used for changes to our operating assets and liabilities of $1.1 million. Research and development expenses were $14.4 million during the third quarter of 2018 compared with $9.6 million for the third quarter of 2017. The increase was attributable to an increase in personnel-related expenses of $2.8 million, of which $1.4 million was related to non-cash stock-based compensation expense, $1.6 million for direct research and development activities and $0.3 million for facilities-related costs. General and administrative expenses were $4.4 million during the third quarter of 2018 compared with $2.5 million for the third quarter of 2017. The increase was predominantly due to $1.5 million in personnel-related expenses, of which $0.7 million was related to non-cash stock-based compensation expense and $0.5 million increase in expenses related to operating as a public company. The change in estimated fair value of contingent consideration expense of $0.6 million during the third quarter of 2018 relates to the value of shares potentially issuable under two commercial agreements. About UNITY UNITY is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to statements related to the expected timing for the data read out from our Phase 1 clinical study of UBX0101 and the filing of our next two INDs and our potential to bring medicines to market to treat age-related diseases and extend human healthspan. Such forward-looking statements involve substantial risks and uncertainties that could cause UNITY’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug discovery and development process, including UNITY’s early stage of development and our understanding of senescence biology and other fundamental biological processes associated with aging, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, UNITY’s ability to successfully protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations and the availability or commercial potential of UNITY’s product candidates. UNITY undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see UNITY’s recently filed Registration Statement on Form S-1 and any subsequent current and periodic reports filed with the Securities and Exchange Commission. Unity Biotechnology, Inc. Condensed Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Operating expenses: Research and development $ 14,353 $ 9,599 $ 42,577 $ 25,782 General and administrative 4,389 2,484 11,688 7,040 Fair value of contingent consideration 635 — 2,393 — Total operating expenses 19,377 12,083 56,658 32,822 Operating loss (19,377 ) (12,083 ) (56,658 ) (32,822 ) Interest income 1,068 348 2,246 734 Other expense, net (37 ) (15 ) (70 ) (25 ) Net loss (18,346 ) (11,750 ) (54,482 ) (32,113 ) Other comprehensive loss Unrealized gain (loss) on marketable securities, net of tax (42 ) 16 (15 ) (4 ) Comprehensive loss $ (18,388 ) $ (11,734 ) $ (54,497 ) $ (32,117 ) Net loss per share, basic and diluted $ (0.45 ) $ (3.63 ) $ (2.29 ) $ (10.17 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 41,057,861 3,236,760 23,762,450 3,157,505 Unity Biotechnology, Inc. Condensed Balance Sheets (In thousands) September 30, December 31, 2018 2017 (Unaudited) Assets Current Assets: Cash and cash equivalents $ 28,897 $ 7,298 Contribution receivable — 1,382 Short-term marketable securities 148,917 79,212 Prepaid expenses and other current assets 2,002 988 Total current assets 179,816 88,880 Property and equipment, net 6,345 6,958 Long-term marketable securities 6,386 5,118 Restricted cash 550 550 Other long-term assets 1,624 518 Total assets $ 194,721 $ 102,024 Liabilities, convertible preferred stock, and stockholders' equity (deficit) Current liabilities: Accounts payable $ 2,624 $ 2,378 Accrued compensation 2,839 2,181 Accrued and other current liabilities 4,618 3,338 Contingent consideration liability, current portion 1,609 — Total current liabilities 11,690 7,897 Deferred rent, net of current portion 2,667 3,166 Contingent consideration liability, net of current portion 784 — Other non-current liabilities 64 118 Total liabilities 15,205 11,181 Convertible preferred stock — 173,956 Stockholders' equity (deficit): Common stock 4 1 Additional paid-in capital 321,594 4,072 Related party promissory notes for purchase of common stock (201 ) (202 ) Employee promissory notes for purchase of common stock (400 ) — Accumulated other comprehensive loss (119 ) (104 ) Accumulated deficit (141,362 ) (86,880 ) Total stockholders' equity (deficit) 179,516 (83,113 ) Total liabilities, convertible preferred stock, and stockholders' equity (deficit) $ 194,721 $ 102,024 Investors Endurance Advisors Elizabeth Broder email@example.com Media Austine Graff 1-650-443-6725 firstname.lastname@example.org Source: Unity Biotechnology, Inc.